Adjunct Senior Research Fellow, Institute for Molecular Bioscience
Affiliate Professor, Queensland Brain Institute, The University of Queensland
On May 12, 2021, Jake Gratten and Naomi Wray will present findings from the Australian Autism Biobank study, an initiative to establish an Australian resource of biospecimens, phenotypes and genomic data for autism research.
Small molecules, genes and antisense oligonucleotides: Industry perspectives on treatment development for ASD
Vice President, Head of Clinical Science, Axial Therapeutics
Stuart Cobb, Ph.D.
Chief Scientific Officer, Neurogene; Research Fellow, University of Edinburgh
Yael Weiss, M.D., Ph.D.
Vice President, Business Development, Ultragenyx
Randy Carpenter, M.D.
Chief Medical Officer, Rett Syndrome Research Trust; Co-Founder, Allos Pharma
On May 14, 2021, Federico Bolognani, Stuart Cobb, and Yael Weiss will join a panel to discuss new industry developments on the use of small molecules, gene therapy and antisense oligonucleotides as treatment approaches for autism spectrum disorders (ASD). The panel discussion will be moderated by Randall Carpenter.
On May 20, 2021, the SFARI science team will hold an informational session to answer questions about the 2021 Genomics of ASD: Pathways to Genetic Therapies request for applications.
Chief Clinical Officer, Dascena
Joseph Buxbaum, Ph.D.
Director, Seaver Autism Center
Professor, Psychiatry, Neuroscience, Genetics and Genomic Sciences
Vice Chair for Research and Vice Chair for Mentoring, Psychiatry, Icahn School of Medicine at Mount Sinai
Heather Mefford, M.D., Ph.D.
Full Member, St. Jude Children’s Research Hospital
On May 21, 2021, David Ledbetter and Joseph Buxbaum will discuss whether there are genes for which mutations confer risk specific to autism or whether these genes are really conferring general risk of disrupted brain development. The discussion will be moderated by Heather Mefford.
Emmanuel Mignot discussed sleep biology as well as sleep disorders and their impact. He presented a link to what is known on the genetics of sleep and sleep disorders. He emphasized the need for large scale objective sleep recording studies with genomic and proteomic analysis to better understand the molecular pathways regulating sleep and circadian biology.
From parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndrome
Allyson Berent discussed the journey that led her to becoming chief science officer of the largest research funding foundation for Angelman syndrome in the world (Foundation for Angelman Syndrome Therapeutics [FAST]), and the cofounder and chief operating officer of GeneTx Biotherapeutics — a biotech company solely focused on developing an antisense oligonucleotide for the treatment of Angelman syndrome — after her daughter was diagnosed with Angelman syndrome at 5.5 months old.
Associate Professor in Medicine, Harvard Medical School
Associated Researcher, Broad Institute
Benjamin Neale discussed progress in mapping genetic risk factors for autism, schizophrenia and bipolar disorder.
Adjunct Scientist, Mouse Imaging Centre, The Hospital for Sick Children
Associate Professor in Medical Biophysics, University of Toronto
On January 29, 2020, Jason Lerch explored this question: What do modern ways of looking at brains and genes tell us about autism – or autisms – and its relation to attention deficit disorder, obsessive-compulsive disorder and other related disorders of brain development?
On November 20, 2019, Graeme Davis presented his research investigating the mechanisms that lie at the interface between neuronal homeostatic plasticity and ASD genetics.
On October 30, 2019, Gloria Choi discussed her work using mouse models of maternal immune activation to study the role of maternal infection in neurodevelopmental disorders, such as autism spectrum disorder.